ImmunityBio (IBRX) traded higher as market attention returned to the company’s recently disclosed capital raise and balance-sheet actions, a common catalyst for small- and mid-cap biopharma names after volatility. In late March, the company announced $75 million of non-dilutive funding under its existing royalty-based financing agreement and disclosed a simultaneous $25 million conversion of a promissory note into common shares, actions that investors often interpret as improving liquidity runway while reducing debt. (ir.immunitybio.com)

The March 31 package combined additional funding capacity under a Royalty Interest Purchase Agreement and a founder-affiliated note conversion, which reduced outstanding debt while boosting cash resources to support commercial scaling and global expansion. Traders frequently revisit these items on quiet news days, especially when a stock has been sensitive to funding risk or perceived dilution. (ir.immunitybio.com)

The stock’s uptick also arrives just days before ImmunityBio is expected to report quarterly results, with market calendars pointing to a Q1 2026 release before the open on May 11, 2026. Event-driven positioning into earnings can amplify day-to-day moves, particularly in names tied to a single major commercial product and headline-driven sentiment. (marketbeat.com)

While today’s move appears tied more to financing/positioning than fresh regulatory headlines, ImmunityBio remains under an active regulatory spotlight in 2026. The FDA posted a March 13, 2026 warning letter focused on promotional communications for ANKTIVA, which has previously driven sharp share-price reactions and continues to be a key risk variable for traders. (fda.gov)